早期乳腺癌免疫治疗:为时过早、过于肤浅还是恰到好处?
本文是一篇关于早期乳腺癌免疫治疗的观点性综述。文章指出免疫治疗已成为乳腺癌新治疗模式,PD-L1过表达的转移性三阴性乳腺癌已批准免疫联合化疗一线治疗。由于免疫检查点抑制剂单药在晚期乳腺癌中临床活性有限,联合治疗模式受到关注,尤其在早期疾病中快速开发。早期乳腺癌中大量正在进行的免疫治疗试验开展之际,晚期疾病中的可靠数据仍不完善。本综述对在早期乳腺癌中确立免疫治疗药物疗效和安全性的努力提出了观点。
要点
- 免疫检查点抑制剂单药在晚期乳腺癌中临床活性有限。
- 早期乳腺癌中大量免疫治疗试验正在进行,但晚期疾病可靠数据仍不完善。
- 本综述对早期乳腺癌免疫治疗疗效与安全性的确立提出了观点。
核心结论
- 早期乳腺癌免疫治疗的疗效与安全性尚待确立,当前晚期疾病数据仍不完善。
研究设计与样本
- 本文为观点性综述,检索范围未在摘要中报告。
主要发现
- 免疫检查点抑制剂单药在晚期乳腺癌中临床活性有限。
- PD-L1过表达的转移性三阴性乳腺癌已批准免疫联合化疗一线治疗。
- 早期乳腺癌中大量免疫治疗试验正在进行。
局限性
- 晚期疾病中的可靠数据仍不完善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunotherapy emerged as a new treatment modality for breast cancer, and its use is approved in combination with chemotherapy for first-line therapy in metastatic triple-negative breast cancer overexpressing PD-L1. As immune checkpoint inhibitors alone have modest clinical activity in advanced breast cancer, there is a growing interest in combinatorial modalities, and particularly for their rapid development in the early disease setting. The plethora of ongoing immunotherapy trials in early breast cancer comes at a time when solid data in advanced disease are still imperfect. This review offers a perspective on the efforts to establish the efficacy and safety of immunotherapeutic agents in early breast cancer.
引用
- Franzoi MA, Romano E, Piccart M, et al. Immunotherapy for early breast cancer: too soon, too superficial, or just right? Ann Oncol. 2020. PMID: 33307202. doi:10.1016/j.annonc.2020.11.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。